SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is capturing significant community attention due to its low circulating supply and small market capitalization, fueling speculation among traders about the potential for rapid gains. Supporters are actively encouraging accumulation in anticipation of a breakout, while others remain cautious, debating the project's long-term utility versus its status as a volatile speculative play.

EOG Resources, Inc. engages in the exploration, development, production and marketing of crude oil and natural gas. It operates through the United States, Trinidad, and Other International geographical segments. The Other International segment includes China and Canada operations. The company was founded in 1985 and is headquartered in Houston, TX.

EOG Resources, Inc.

EOG Resources is capturing investor attention following a significant $5.6 billion acquisition of Encino Acquisition Partners in the Utica Shale, a move that aims to bolster production capacity and long-term shareholder value. Community discussions remain focused on the company's operational discipline and dividend reliability as investors weigh its aggressive growth strategy against the backdrop of fluctuating energy commodity prices.

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics is trending following a significant strategic reprioritization that includes a workforce reduction and the termination of several key partnerships, sparking intense debate among investors about the company's long-term viability and the status of its pipeline. The community is actively discussing the recent departure of high-level executives and the extended delays in critical data readouts, with many expressing frustration over the persistent decline in share price relative to their initial cash-backed valuations.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending as investors weigh its upcoming FDA Type A meeting to discuss the recent complete response letter for its lead melanoma drug, RP1. While the community remains divided over the likelihood of an accelerated approval pathway, many are closely monitoring the stock for potential rebound opportunities driven by strong clinical data and a significant cash runway.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The DJT stock is currently at the center of heated online debate as community members clash over the administration's military actions in the Middle East and the resulting impact on the global economy. Investors and critics alike are actively discussing recent reports of downed aircraft, questions regarding the administration's strategic goals, and the potential long-term financial consequences of the ongoing conflict.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

The YETH ETF is currently in the spotlight as investors navigate its transition to a weekly distribution model while balancing potential for consistent income against the underlying volatility of Ethereum. Community members are actively debating the fund's NAV performance and comparing its distribution yields to broader crypto-linked assets, with many split between using it as a tactical income tool or a long-term holding.

Clear Secure, Inc. is a secure identity company, which engages in developing biometric identity verification technology platforms. Its identity platform connects passengers to the cards in their wallet transforming the way passengers live, work, and travel, and focuses on providing verification in several areas, such as events, healthcare, and sporting stadiums. The company was founded by Caryn Seidman-Becker and Kenneth Cornick in 2010 and is headquartered in New York, NY.

Clear Secure Inc - Ordinary Shares Class A

Clear Secure is experiencing significant positive sentiment driven by its ongoing expansion into non-airport enterprise sectors and robust quarterly earnings that exceeded analyst expectations. Community members are actively debating the long-term potential of the firm's biometric identity platform, with many highlighting its growth as a critical infrastructure layer in travel, healthcare, and security, while others remain cautious regarding valuation and short-term price volatility.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health (ELV) is currently under intense scrutiny as investors weigh recent strategic cutbacks to its Medicare Advantage footprint against a backdrop of ongoing sector-wide margin pressure and regulatory uncertainty. Community sentiment is deeply divided, with many traders viewing the stock as an undervalued opportunity for a long-term rebound, while others express frustration over its recent price volatility and lack of momentum.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros Inc is trending as traders closely monitor high implied volatility ahead of financial results, with the community actively debating whether the companys aggressive expansion and strong transaction volume can justify its premium valuation in a challenging macroeconomic environment. Market participants remain sharply divided, as some point to persistent institutional support and growth potential, while others express caution regarding elevated costs and the sustainability of consumer spending on premium beverages.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit...

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud...

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026...

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage...

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE Skye Bioscience, Inc. Securities Fraud Class...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK...

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 6, 2026 NEW YORK...

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience...

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Skye Bioscience Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$0.698
Prev Close	$0.6649
Open	$0.656
Dividend Yield	0.00%
50-Day Moving Average	$0.7665
Beta	0.95
Avg. Volume	1.07M
PE Ratio	-0.50

52-Week High	$5.75
52-Week Low	$0.5655
Market Capitalization	$23.3M
EPS (Annual)	-$1.41
Price to Book	1.16
Revenue Per Employee	$0.00

SKYE
Skye Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SKYE News

SKYESkye Bioscience Inc